Targeting Cancer Stem Cells—A Renewed Therapeutic Paradigm

Abstract

Metastasis is often accompanied by radio-and chemotherapeutic resistance to anticancer treatments and is the major cause of death in cancer patients. Better understanding of how cancer cells circumvent therapeutic insults and how disseminated cancer clones generate life-threatening metastases would therefore be paramount to the development of effective therapeutic approaches for clinical management of malignant disease. Mounting reports over the past two decades have provided evidence for the existence of a minor population of highly malignant cells within liquid and solid tumors, which are capable of self-renewing and of regenerating secondary growths with the heterogeneity of the primary tumors from which they derive. These cells, called tumor-initiating cells or cancer stem cells (CSCs) exhibit increased resistance to standard radio-and chemotherapies and appear to have mechanisms that enable them to evade immune surveillance. CSCs are therefore considered to be responsible for systemic residual disease after cancer therapy, as well as for disease relapse. How CSCs develop, the nature of the interactions they establish with their microenvironment, their phenotypic and functional characteristics, as well as their molecular dependencies have all taken center stage in cancer therapy. Indeed, improved understanding of CSC biology is critical to the development of important CSC-based anti-neoplastic approaches that have the potential to radically improve cancer management. Here, we summarize some of the most pertinent elements regarding CSC development and properties, and highlight some of the clinical modalities in current development as anti-CSC therapeutics.

Differentiation of Cancer Stem Cells by Using Synthetic Small Molecules: Toward New Therapeutic Strategies against Therapy Resistance

“…To make a non‐exhaustive list, CD44, CD47, CD123 (CD standing for cluster of differentiation), ALDH (aldehyde dehydrogenase), EpCAM (epithelial cell adhesion molecule), TGFβ (transforming growth factor beta) or IGF (insulin‐like growth factor) receptors are among the most known and studied markers. However, there are a number of other markers that have been identified and such cell‐surface markers are not universal, even within the same tumor type, thus rendering their identification and targeting complicated [24] …”